Galleri (cancer test)

2022: Technology Announcement

In mid-September 2022, doctors from the Memorial Sloan Kettering Cancer Center New York conducted clinical studies of a new blood testing technology that determines most species. cancer We are talking about the Galleri system developed by the company. Grail

During the study, a blood test was carried out in more than 6 thousand patients aged 50 years and older. The test identified dozens of new cases of the disease, with many of the species at an early stage and three-quarters being the forms not routinely screened for. Further diagnosis confirmed the presence of serious tumors or blood cancer in 35 people, or 1.4% of the total cohort. The analysis also revealed two cancers in one woman who turned out to have breast and endometrial tumors.

Doctors from Memorial Sloan Kettering Cancer Center conducted clinical studies of a new blood test technology

The Galleri test has been described as a potential tipping point in NHS England, which is due to present the results of a major trial of 165,000 people in 2023. Doctors hope the test will save lives by detecting cancer early enough for surgery and treatment to be more effective, but the technology is still under development.

{{quote 'Blood tests to detect several cancers used to be in the science fiction field, but they are now an area of cancer research that shows promise for patients. Studies like this are critical to making progress on late-stage cancer and giving more patients a chance of a good outcome. The results of the Pathfinder study give us a better understanding of how often cancer is detected by this blood test in people who have not previously been diagnosed, "said Naser Turabi, director of evidence and implementation at Cancer Research UK. }} In addition to detecting the presence of the disease, the test predicts where the cancer is, allowing doctors to speed up the follow-up work needed to detect and confirm the cancer. The test identified 19 solid tumors in tissues such as the breast, liver, lungs and colon, as well as ovarian and pancreatic cancers, which are usually found at an advanced stage and have low survival rates. The remaining cases were linked to blood cancer. Of the 36 cancers found in total, 14 were early stage and 26 were forms of the disease that are not screened regularly. Further analysis showed that the blood test was negative in 99.1% of non-cancer sufferers, meaning that only a small proportion of healthy people mistakenly tested positive. About 38% of those who tested positive had cancer.^[1]

Notes